Who are Pramipexole (Mirapex)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Neupro, DC, Cabergoline (Dopamine Agonist), combination with dopamine agonist cabergoline, ROP+L-Dopa, DAM.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/pramipexole-mirapex.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Pramipexole (Mirapex) — Competitive Intelligence Brief

Pramipexole (Mirapex) (Pramipexole (Mirapex)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Dopamine agonist. Area: Neurology.

marketed Dopamine agonist D2 dopamine receptor, D3 dopamine receptor Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Pramipexole (Mirapex) (Pramipexole (Mirapex)) — Massachusetts General Hospital. Pramipexole is a dopamine agonist that stimulates D2 and D3 dopamine receptors in the brain to restore dopamine signaling.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Pramipexole (Mirapex) TARGET	Pramipexole (Mirapex)	Massachusetts General Hospital	marketed	Dopamine agonist	D2 dopamine receptor, D3 dopamine receptor
Neupro	ROTIGOTINE	UCB	marketed	Nonergot Dopamine Agonist [EPC]	dopamine receptors	2007-01-01
DC	DC	Gary Archer Ph.D.	marketed	dopamine agonist	dopamine receptor
Cabergoline (Dopamine Agonist)	Cabergoline (Dopamine Agonist)	University Hospital, Basel, Switzerland	marketed	Dopamine agonist	Dopamine D2 receptor
combination with dopamine agonist cabergoline	combination with dopamine agonist cabergoline	Ludwig-Maximilians - University of Munich	marketed	Dopamine agonist	Dopamine D2 receptor
ROP+L-Dopa	ROP+L-Dopa	GlaxoSmithKline	marketed	Dopamine agonist + Levodopa combination	Dopamine receptors (D2/D3); Dopamine pathway
DAM	DAM	Beijing Bozhiyin T&S Co., Ltd.	marketed	Dopamine agonist	Dopamine receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Dopamine agonist class)

Sumitomo Pharma America, Inc. · 2 drugs in this class
University Hospital, Toulouse · 2 drugs in this class
Rennes University Hospital · 2 drugs in this class
Britannia Pharmaceuticals Ltd. · 1 drug in this class
Desitin Arzneimittel GmbH · 1 drug in this class
GlaxoSmithKline · 1 drug in this class
Intec Pharma Ltd. · 1 drug in this class
Leiden University Medical Center · 1 drug in this class
Ludwig-Maximilians - University of Munich · 1 drug in this class
Massachusetts General Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Pramipexole (Mirapex) — Competitive Intelligence Brief. https://druglandscape.com/ci/pramipexole-mirapex. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab